ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements
Auro Laboratories Ltd reported revenue from operations of ₹8.8 Cr (+214.3% YoY) and net profit of ₹1 Cr for Q1 FY27.
Auro Laboratories Limited held its 37th Annual General Meeting on August 11, 2026, via video conferencing. The company conducted all items of business as listed in the notice.
Auro Laboratories Ltd has scheduled a board meeting on August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Auro Laboratories issued a notice to shareholders regarding its 37th AGM scheduled for August 11, 2026. The letter provides web-links to access the FY 2025-26 Annual Report.
Auro Laboratories has scheduled its 37th Annual General Meeting for August 11, 2026. Agenda includes adopting financial statements and re-appointing Mr. Kiran Kulkarni as Whole-Time Director.
Auro Laboratories released its Annual Report for FY 2025-26. The 37th Annual General Meeting is scheduled for August 11, 2026, via video conferencing.
Auro Laboratories re-appointed Mr. Kiran Suresh Kulkarni as Whole Time Director. The three-year term starts May 24, 2027, subject to shareholder approval.
Auro Laboratories Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report indicates overall adherence to SEBI regulations and statutory norms.
Auro Laboratories Ltd reported revenue from operations of ₹9.8 Cr (+32.4% YoY) and net profit of ₹1 Cr (+150.0% YoY) for Q4 FY26.
Auro Laboratories approved its audited financial results for the year ended March 31, 2026. The company also appointed a new CFO and auditors for FY 2026-27.
Mr. Kuntal Pancholi resigned as Chief Financial Officer and Key Managerial Personnel of Auro Laboratories effective May 28, 2026. He cited personal reasons for his departure.
Auro Laboratories scheduled a board meeting for May 29, 2026, to approve audited financial results. The trading window remains closed until 48 hours post-announcement.
Auro Laboratories Limited received an 'Attestation of Inspection' from the EDQM for its MIDC Tarapur facility. The certification confirms compliance with EU Good Manufacturing Practice (GMP) standards for Metformin Hydrochloride. This regulatory milestone validates the facility's quality standards for European market requirements.
Auro Laboratories Ltd has received a Certificate of GMP Compliance (No. 26-0002) from Swissmedic for its manufacturing facility in Tarapur, Maharashtra. The certification confirms compliance with GMP requirements under the EU-Switzerland Mutual Recognition Agreement, validating the plant's quality standards for therapeutic products.
Auro Laboratories Limited received new credit ratings from Acuite Ratings & Research Limited for ₹79.80 Crore in bank facilities. Long-term facilities were assigned 'ACUITE BB+' and short-term facilities 'ACUITE A4+', both with a 'Stable' outlook. The ratings reflect the promoters' extensive experience and a moderate financial risk profile despite recent capex-related revenue declines.